Blood 2018 Apr 5
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.   

Related Questions


What would you want community oncologists to know when following these patients? Are there any other special issues to follow especially in AYA?

For example, if patients are unable to receive continuous infusion from home health agencies, or if prolonged hospitalization is cost-prohibitive.&nbs...